Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported financial results and recent highlights for the third quarter ended September 30.
“The third quarter was highlighted by Genentech’s BLA filing for rituximab in a subcutaneous formulation using Halozyme’s ENHANZE platform in multiple blood cancers, a development that adds to the potential for our royalty revenue and highlights the benefits of our business model,” said Dr. Helen Torley, president and chief executive officer. “In our oncology pillar, we continued initiation of our global sites in our phase 3 study of PEGPH20 and are making progress toward dose expansion in our study with Keytruda, all as we anticipate reporting topline results from stage 2 of our HALO-202 study once the data is mature.”
Halozyme was recently informed by the independent statistician for the data monitoring committee of its HALO-202 study that progression-free survival data are not yet mature for analysis. As a result, the company now expects the reporting of data may move into 2017, depending on when it is mature for analysis.
Third Quarter 2016 and Recent Highlights include:
- The inclusion of PEGPH20 in the Pancreatic Cancer Action Network’s Precision Promise initiative, a broad industry and pancreatic cancer community coalition established to study pancreatic cancer therapies in patients based on the molecular profile of their tumors. The clinical trial plans to enroll patients at 12 consortium sites in the U.S. beginning in spring 2017.
- Continuing to initiate sites in the HALO-301 | Pancreatic study toward the goal of having approximately 90 percent of centers ready to screen patients by the end of 2016.
- Progressing in dose escalation of the ongoing phase 1b clinical study evaluating PEGPH20 in combination with KEYTRUDA® (pembrolizumab) in relapsed non-small cell lung and gastric cancer patients. The company continues to project that the study will move to the dose expansion phase by the end of 2016.
- U.S. Food and Drug Administration (FDA) filing a Biologics License Application (BLA) to support approval for the subcutaneous formulation of Rituximab in multiple blood cancer indications. Including all approved indications, Roche reported total 2015 sales of rituximab in the United States of 3.76 billion CHF.
- Pfizer announcing discontinuation of the global clinical development program for bococizumab, its investigational PCSK9 inhibitor. The development of a subcutaneous version on the Halozyme ENHANZE platform has also been discontinued. Pfizer also made a portfolio decision to discontinue development of rivipansel with the ENHANZE platform even though the technology performed as intended. Pfizer continues to develop an additional program with the ENHANZE platform for an undisclosed target.
Third Quarter 2016 Financial Highlights
- Revenue for the third quarter was $31.9 million compared to $20.8 million for the third quarter of 2015, driven primarily by royalties from partner sales of Herceptin® SC, MabThera® SC and HYQVIA®, API sales to partners, and manufacturing and clinical supply reimbursements from ENHANZE™ partners.
Revenue for the third quarter included $13 million in royalties, an increase of 58 percent from the prior-year period, $9.6 million in sales of bulk rHuPH20 primarily for use in manufacturing collaboration products and $3.7 million in HYLENEX® recombinant (hyaluronidase human injection) product sales.
- Research and development expenses for the third quarter were $33.9 million, compared to $27.6 million for the third quarter of 2015. The planned increases were primarily due to a ramp in spending associated with the HALO-301 study, personnel expenses, and manufacturing and clinical supply expenses that are reimbursed by ENHANZE™ partners.
- Selling, general and administrative expenses for the third quarter were $11.6 million, compared to $10.2 million for the third quarter of 2015. The increase was primarily due to personnel expenses, including stock compensation, for the period.
- Net loss for the third quarter was $28.9 million, or $0.23 per share, compared to a net loss in the third quarter of 2015 of $24.5 million, or $0.19 per share.
- Cash, cash equivalents and marketable securities were $221.1 million at September 30 compared to $230 million at June 30, 2016.
Financial Outlook for 2016
For the full year 2016, the company updated and narrowed its financial guidance, now expecting:
- Net revenue of $145 million to $150 million, raising the lower end of its prior $140 million to $150 million range;
- Operating expenses of $240 million to $245 million, from the prior $245 million to $260 million range;
- Cash flow of $75 million to $85 million, from the prior range of $65 million to $85 million;
- Year-end cash balance of $180 million to $190 million, raising the lower end of its prior $170 million to $190 million range. (Original Source)
Shares of Halozyme Therapeutics closed today at $8.87, up $0.41 or 4.85%. HALO has a 1-year high of $18.61 and a 1-year low of $6.96. The stock’s 50-day moving average is $11.60 and its 200-day moving average is $10.03.
On the ratings front, Halozyme has been the subject of a number of recent research reports. In a report issued on November 3, Deutsche Bank analyst Andrew Peters initiated coverage with a Buy rating on HALO and a price target of $12, which represents a potential upside of 40% from where the stock is currently trading. Separately, on November 1, Canaccord’s Arlinda Lee reiterated a Buy rating on the stock and has a price target of $14.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Andrew Peters and Arlinda Lee have a yearly average loss of 22.0% and 16.4% respectively. Peters has a success rate of 35% and is ranked #3928 out of 4162 analysts, while Lee has a success rate of 28% and is ranked #3983.
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel oncology therapies that target the tumor microenvironment. Its investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies.